Skip to main content
Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.
Claims data analysis of 11248 matched patients starting abatacept or TNFi showed the risk of hospitalized infection was 37 ABA vs 47 TNFi HR 078 95 CI

Dr. John Cush RheumNow

7 years 6 months ago
Claims data analysis of 11,248 matched patients starting abatacept or TNFi showed the risk of hospitalized infection was 37 ABA vs 47 TNFi (HR 0.78; 95% CI 0.64-0.95). Thus ABA was associated with a 22% less risk any hospitalized infection. https://t.co/Ij6b0IYcAZ
A crosssectional study included 1276 RA outpatients showed the prevalence of dysfunctional LBP was 328 Risk factors include BMI OR 1116 P lt 0001

Dr. John Cush RheumNow

7 years 6 months ago
A cross-sectional study included 1276 RA outpatients showed the prevalence of dysfunctional LBP was 32.8%. Risk factors include BMI (OR 1.116; P < 0.001), onset age, disease duration of RA, MTX use, vertebral Fx, facet erosion, DAS-28CRP, pelvic tilt https://t.co/tg8cRImHdM
QD Clinic Smoking amp RA RheumNow Smoking ignites worsens RA How to stop smoking httpstco1K1Lal8KRB

Dr. John Cush RheumNow

7 years 6 months ago
QD Clinic - Smoking & RA | RheumNow - Smoking ignites, worsens RA. How to stop smoking. https://t.co/1K1Lal8KRB
QD Clinic - Smoking & RA
Smoking ignites, worsens RA. How to stop.
New guidelines on the  "Pharmacologic Management of Osteoporosis in Postmenopausal Women," were presented March 25 at ENDO 2019 - The Endocrine Society Annual Meeting and simultaneously published online in the Journal of Clinical Endocrinology & Metabolism. 
An observational study published in Annals of Internal Medicine finds that emergency department (ED) visits attributable to inhaled cannabis are more frequent than those attributable to edible cannabis, although the latter is associated with more acute psychiatric visits and more ED visits than expected.
THe gender gap has decreased from 2017 to now by nearly 15k 105000 to a 90490 difference between female and male physicians with less difference in Bi

Dr. John Cush RheumNow

7 years 6 months ago
THe gender gap has decreased from 2017 to now by nearly $15k ($105,000 to a $90,490 difference between female and male physicians) with less difference in Birmingham, Bridgeport, Milwaukee, jacksonville but more in Louisville, N.Orleans, Austin & Dallas. https://t.co/U7xjJHPd0O
2019 Doximity report shows Rheumatologists are the 14th lowest paid of all medical specialties but is amongst the lowest with a gender gap difference

Dr. John Cush RheumNow

7 years 6 months ago
2019 Doximity report shows Rheumatologists are the 14th lowest paid of all medical specialties; but is amongst the lowest with a gender gap difference. check it out here https://t.co/j3YOybQ78n
Murine BMderived macrophages or human monocytes treated w tofacitinib or selective JAK1 JAK3 inhibitors Both TOFA amp JAK1i but not JAK3i effectively

Dr. John Cush RheumNow

7 years 6 months ago
Murine BM–derived macrophages or human monocytes treated w/ tofacitinib or selective JAK1, JAK3 inhibitors. Both TOFA & JAK1i but not JAK3i effectively inhibited STAT1 phosphorylation & IFN gamma production, suggesting affects on macrophage function. https://t.co/qILxzCDrCH
What clinical features best identify early systemic lupus erythematosus (SLE) patients from mimics?  A multicenter, multinational study aimed to evaluate manifestations at disease onset and to compare early SLE manifestations to those of diseases mimicking SLE.
QD Clinic - Pushing to LDAS or Remission
Great response in PsA, but is it enough?
Boehringer Ingelheim announce s FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD httpstcoBQz94Kg4Px

Dr. John Cush RheumNow

7 years 6 months ago
Boehringer Ingelheim announce s FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD https://t.co/BQz94Kg4Px
×